CIIE is an important window for China to share market opportunities with the world under the "dual circulation" strategy. It provides China with a platform to embrace openness and showcase innovative results, and also brings opportunities for mutual benefits and inclusiveness to the world.

GSK has a history in China for over a century with a constant commitment to helping improve the health, life and future of Chinese people.

In the future, we will further leverage our advantages and expertise in the fields of pharmaceuticals and vaccines, continue to expand our business in China, step up efforts to introduce innovative healthcare solutions, and continuously improve the accessibility of high-quality medical resources. We aim to enable high-quality innovative healthcare solutions to benefit more Chinese people and contribute to the Healthy China Initiative.